DAXXIFY

Serial Number 97809052
Registration 7836568
700

Registration Progress

Application Filed
Feb 23, 2023
Under Examination
Feb 27, 2024
Approved for Publication
Jan 2, 2024
Published for Opposition
Jan 2, 2024
Registered
Jun 17, 2025

Trademark Image

DAXXIFY

Basic Information

Serial Number
97809052
Registration Number
7836568
Filing Date
February 23, 2023
Registration Date
June 17, 2025
Published for Opposition
January 2, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 17, 2025
Registration
Registered
Classes
005

Rights Holder

Revance Therapeutics, Inc.

03
Address
UNIT 8, THE OLIVIA CENTRE
373-375 ANTRIM ROAD
GLENGORMLEY BT365EB
GB

Ownership History

Revance Therapeutics, Inc.

Original Applicant
03
Newark, CA

Revance Therapeutics, Inc.

Owner at Publication
03
Newark, CA

Revance Therapeutics, Inc.

Original Registrant
03
GLENGORMLEY GB

Legal Representation

Attorney
Jennifer Waitman

USPTO Deadlines

Next Deadline
1962 days remaining
Section 8 Declaration Due (Principal Register)
Due Date
June 17, 2031
Grace Period Ends
December 17, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

28 events
Date Code Type Description Documents
Jan 20, 2026 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jan 20, 2026 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jan 20, 2026 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Aug 4, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 4, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Aug 4, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Aug 4, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Aug 4, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jun 17, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jun 17, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 23, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
May 23, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
May 12, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Feb 20, 2025 IUAF S USE AMENDMENT FILED Loading...
May 9, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Feb 20, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Aug 27, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 27, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Aug 27, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 27, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 27, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 2, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 2, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 13, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 27, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 21, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 14, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 27, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, muscle spasms, and pain; pharmaceutical preparations, namely, peptide substrates for use in the treatment of neurological disorders, muscle dystonias, muscle spasms, and pain
First Use Anywhere: Sep 26, 2022
First Use in Commerce: 20231000

Classification

International Classes
005